FDA USE OF EUROPEAN CE MARK TO STREAMLINE DEVICE REVIEW PROCESS UNDER DISCUSSION; AGENCY STAFFERS SOUND REGULATORY REFORM THEME AT FDLI MEETING
This article was originally published in The Gray Sheet
Executive Summary
FDA is exploring use of the CE mark of product approval in Europe to replace scientific data requirements in the device review process, Philip Phillips, deputy director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health, said Dec. 13 at the Food and Drug Law Institute's annual education conference in Washington, D.C.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.